Hopkins, A.M.; Kichenadasse, G.; Abuhelwa, A.Y.; McKinnon, R.A.; Rowland, A.; Sorich, M.J.
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”. Cancers 2021, 13, 3763.
https://doi.org/10.3390/cancers13153763
AMA Style
Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ.
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”. Cancers. 2021; 13(15):3763.
https://doi.org/10.3390/cancers13153763
Chicago/Turabian Style
Hopkins, Ashley M., Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, and Michael J. Sorich.
2021. "Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”" Cancers 13, no. 15: 3763.
https://doi.org/10.3390/cancers13153763
APA Style
Hopkins, A. M., Kichenadasse, G., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., & Sorich, M. J.
(2021). Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”. Cancers, 13(15), 3763.
https://doi.org/10.3390/cancers13153763
